Reply to rituximab activity in CD20 positive multiple myeloma

被引：4
|
作者：
Gozzetti, A. [1 ]
Fabbri, A.
Lazzi, S.
Bocchia, M.
Lauria, F.
机构：
[1] Univ Siena, Dept Med & Immunol Sci, Div Hematol & Transplants, I-53100 Siena, Italy
[2] Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy
来源：
LEUKEMIA | 2007年 / 21卷 / 08期
关键词：
D O I：
10.1038/sj.leu.2404702
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1842 / 1843
页数：2
相关论文
共 50 条
  • [21] STUDY ON THE PRONOTIC IMPACT OF CD117 IN PATIENTS WITH MULTIPLE MYELOMA (MM) CD20 POSITIVE. EXPERIENCE OF A SINGLE CENTER
    Moret Puig, C.
    Santos Carvajal, N. Y.
    Blanco Benigno, A.
    Tuset Andujar, E.
    Cruz Garcia, D.
    Lloveras Guelque, N.
    Coll Jorda, R.
    Guardia Sanchez, R.
    Roncero Vidal, J. M.
    Kelleher, N.
    Sagues Serrano, M.
    Diaz Santa, J.
    Mostacedo Marasovic, S.
    Bustins Tarrats, A.
    Buxo, M.
    Gallardo Giralt, D.
    Gonzalez Montes, Y.
    HAEMATOLOGICA, 2017, 102 : 305 - 306
  • [22] SRC INHIBITORS DOWNREGULATE CD20 AND MODULATE THE ACTIVITY OF THE CD20 PROMOTER
    Winiarska, M.
    Bojarczuk, K.
    Pyrzynska, B.
    Miazek, N.
    Zapala, P.
    Bobrowicz, M.
    Dwojak, M.
    Siernicka, M.
    Golab, J.
    HAEMATOLOGICA, 2014, 99 : 45 - 45
  • [23] Apparent modulation of CD20 by rituximab: an alternative explanation
    Cragg, MS
    Bayne, MC
    Illidge, TM
    Valerius, T
    Johnson, PWN
    Glennie, MJ
    BLOOD, 2004, 103 (10) : 3989 - 3990
  • [24] CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype
    Paino, Teresa
    Ocio, Enrique M.
    Paiva, Bruno
    San-Segundo, Laura
    Garayoa, Mercedes
    Gutierrez, Norma C.
    Eugenia Sarasquete, M.
    Pandiella, Atanasio
    Orfao, Alberto
    San Miguel, Jesus F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (07): : 1110 - 1114
  • [25] Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: Safety and efficacy evaluation
    Laurenti, Luca
    De Padua, Laura
    Battendieri, Remo
    Tarnani, Michela
    Sica, Simona
    Blasi, Maria Antonietta
    Savino, Gustavo
    Leone, Giuseppe
    LEUKEMIA RESEARCH, 2011, 35 (05) : 682 - 684
  • [26] Influence of cytokines on CD20 expression and Rituximab-induced CDC on MC/CAR myeloma cells
    Umeda, M
    Kuraishi, Y
    Nakai, S
    Furukawa, K
    Akahane, S
    Tsuru, H
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 100 : 99P - 99P
  • [27] Interferon-γ induces CD20 expression on multiple myeloma cells via induction of Pu.1 and augments rituximab binding to myeloma cells.
    Treon, SP
    Shima, Y
    Raje, N
    Tai, YT
    Hideshima, T
    Chauhan, D
    Grossbard, ML
    Preffer, FI
    Doss, S
    Schlossman, R
    Szczepek, R
    Belch, AR
    Pilarski, LM
    Anderson, KC
    BLOOD, 1999, 94 (10) : 119A - 119A
  • [28] A Case of Cd20 Positive Mediastinal Rhabdomyosarcoma
    Diniz, Gulden
    Genel, Ferah
    Yucel, Nur
    Turedi, Aysen
    Vergin, Canan
    TURKISH JOURNAL OF PATHOLOGY, 2012, 28 (03) : 270 - 273
  • [29] Mutation of CD20 gene causes resistance to therapy with rituximab
    Terui, Y
    Sakurai, T
    Mishima, Y
    Mishima, Y
    Yokoyama, M
    Hatake, K
    ANNALS OF ONCOLOGY, 2005, 16 : 78 - 79
  • [30] The intensity of CD20 expression determines the outcome of rituximab treatment
    Novakovic, Barbara Jezersek
    Horvat, Mateja
    Prevodnik, Veronika Koboves
    Novakovic, Srdjan
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2010, 26 : S11 - S11
12345